Cover Image
Read Now

CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) indication : treatment of corneal cystine crystal deposits (CCCDs) in adults and children from 2 years of age with cystinosis

The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosi...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health June 2019, 2019
Edition:Version: Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Canada
Cysteamine / Therapeutic Use
Cystinosis / Complications
Cost-benefit Analysis
Corneal Diseases / Drug Therapy
Corneal Diseases / Etiology
Ophthalmic Solutions / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that cysteamine hydrochloride (CH) 0.55% ophthalmic solution be reimbursed for the treatment of CCCDs in adults and children from two years of age with cystinosis only if the following conditions are met: Patient has a diagnosis of cystinosis and evidence of CCCDs; Patient must be under the care of an ophthalmologist experienced in the management of the ocular manifestations of cystinosis; Reduction in price
Item Description:"Final."
Physical Description:1 PDF file (8 pages)

Similar Items